You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,119,137


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,119,137
Title:Methods used to treat cancer
Abstract: The invention encompasses methods used in the sensitization and treatment of cancer based upon the expression of SGEF.
Inventor(s): Tran; Nhan (Phoenix, AZ)
Assignee: The Translational Genomics Research Institute (Phoenix, AZ)
Application Number:15/204,969
Patent Claims:1. A method of sensitizing a patient with glioblastoma to a radiation therapy and/or chemotherapy, the method comprising the steps of: administering to the patient with glioblastoma an src-homology 3 domain containing guanine nucleotide exchange factor (SGEF) inhibitor, wherein the SGEF inhibitor sensitizes the glioblastoma to the radiation therapy and/or chemotherapy, and wherein the SGEF inhibitor is a small hairpin RNA targeting the nucleic acid encoding for SGEF.

2. The method of claim 1, wherein the glioblastoma is invasive.

3. The method of claim 2, wherein the SGEF inhibitor converts the invasive glioblastoma to a non-migratory phenotype.

4. The method of claim 1, and further comprising administering a therapeutically effective amount of the radiation therapy and/or chemotherapy to the patient with glioblastoma.

5. The method of claim 4, wherein the radiation therapy and/or chemotherapy comprises the administration of one or more compounds selected from the group consisting of TROY inhibitors, Pyk2 inhibitors, Rac1 inhibitors, Dock180 inhibitors, Dock7 inhibitors, TWEAK inhibitors, Fn14 inhibitors, BAD inhibitors, and PI3k inhibitors, TRAIL, camptothecin, temozolomide and bevacizumab.

6. A method of treating a patient with invasive glioblastoma, the method comprising the steps of: a. sensitizing the patient with invasive glioblastoma by reducing an expression level of Src-homology 3 domain containing guanine nucleotide exchange factor (SGEF) using an SGEF inhibitor, wherein the SGEF inhibitor is a small hairpin RNA targeting the nucleic acid encoding for SGEF; and b. administering a therapeutically effective amount of a radiation therapy and/or chemotherapy to the patient with invasive glioblastoma.

7. The method of claim 6, wherein the radiation therapy and/or chemotherapy comprises the administration of one or more compounds selected from the group consisting of TROY inhibitors, Pyk2 inhibitors, Rac1 inhibitors, Dock180 inhibitors, Dock7 inhibitors, TWEAK inhibitors, Fn14 inhibitors, BAD inhibitors, and PI3k inhibitors, TRAIL, camptothecin, temozolomide and bevacizumab.

8. The method of claim 6, wherein the SGEF inhibitor converts the invasive glioblastoma to a non-migratory phenotype.

9. The method of claim 6, wherein the chemotherapy comprises administering a therapeutically effective amount of temozolomide.

10. The method of claim 6, wherein the radiation therapy comprises the administration of a therapeutically effective amount of radiation.

11. A method of treating a patient with glioblastoma, the method comprising the steps of: a. sensitizing the patient with glioblastoma by reducing an expression level of Src-homology 3 domain containing guanine nucleotide exchange factor (SGEF) by administering to the patient a small hairpin RNA targeting SGEF; and b. administering a therapeutically effective amount of a radiation therapy and/or chemotherapy to the patient with glioblastoma.

12. The method of claim 11, wherein the radiation therapy and/or chemotherapy comprises the administration of one or more compounds selected from the group consisting of TROY inhibitors, Pyk2 inhibitors, Rac1 inhibitors, Dock180 inhibitors, Dock7 inhibitors, TWEAK inhibitors, Fn14 inhibitors, BAD inhibitors, and PI3k inhibitors, TRAIL, camptothecin, temozolomide and bevacizumab.

13. The method of claim 11, wherein the radiation therapy comprises the administration of a therapeutically effective amount of radiation.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.